Abciximab + Abciximab placebo
Phase 3UNKNOWN 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Myocardial Infarction
Conditions
Myocardial Infarction
Trial Timeline
Jan 1, 2005 โ Jan 1, 2010
NCT ID
NCT00638638About Abciximab + Abciximab placebo
Abciximab + Abciximab placebo is a phase 3 stage product being developed by Eli Lilly for Myocardial Infarction. The current trial status is unknown. This product is registered under clinical trial identifier NCT00638638. Target conditions include Myocardial Infarction.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00638638 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Myocardial Infarction